Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Yang, Pei Wen ^a   Hsieh, Min Shu ^a   Huang, Ya Chuan ^a   Hsieh, Ching Yueh ^a   Chiang, Tzu Hsuan ^a   Lee, Jang Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GROWTH FACTOR; PACLITAXEL; VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; EPIDERMAL GROWTH FACTOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903310194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100326     Document Type: Article

References (52)

1. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349: 2241-2252. (Pubitemid 37485141)
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, et al. (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168. (Pubitemid 46640561)
4. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, et al. (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339: 1979-1984. (Pubitemid 29024130)
5. Reid TD, Davies IL, Mason J, Roberts SA, Crosby TD, et al. (2012) Stage for Stage Comparison of Recurrence Patterns after Definitive Chemoradiotherapy or Surgery for Oesophageal Carcinoma. Clin Oncol (R Coll Radiol).
6. Melis M, Weber JM, McLoughlin JM, Siegel EM, Hoffe S, et al. (2011) An elevated body mass index does not reduce survival after esophagectomy for cancer. Ann Surg Oncol 18: 824-831.
7. Islami F, Fedirko V, Tramacere I, Bagnardi V, Jenab M, et al. (2010) Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers - A systematic review and meta-analysis. Int J Cancer.
8. Wu MT, Lee YC, Chen CJ, Yang PW, Lee CJ, et al. (2001) Risk of betel chewing for oesophageal cancer in Taiwan. Br J Cancer 85: 658-660.
9. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80: 213-223.
10. Pawson T, Raina M, Nash P (2002) Interaction domains: from simple binding events to complex cellular behavior. FEBS Lett 513: 2-10. (Pubitemid 34242971)
11. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocrine-Related Cancer 10: 1-21. (Pubitemid 36457237)
12. Dong J, Dai JC, Shu YQ, Pan SY, Xu L, et al. (2010) Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 31: 1080-1086.
13. Sasaki H, Okuda K, Shimizu S, Takada M, Kawahara M, et al. (2009) EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. Journal of Cancer Research and Clinical Oncology 135: 313-318.
14. Perez CA, Chen H, Shyr Y, Courtney R, Zheng W, et al. (2010) The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol 183: 2062-2069.
15. Goncalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, et al. (2008) A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 8: 169.
16. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, et al. (2007) Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol 14: 2150-2158. (Pubitemid 46988271)
17. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, et al. (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Research 60: 854-857. (Pubitemid 30129514)
18. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008) Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer. Oncol Res 17: 167-174.
19. Lee JM, Yang SY, Yang PW, Shun CT, Wu MT, et al. (2011) Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol 18: 2066-2073.
20. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29: 10-14.
21. Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, et al. (1998) Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 4: 2195-2200. (Pubitemid 28415667)
22. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M (2000) Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 6: 1161-1168. (Pubitemid 30159380)
23. Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, et al. (2009) Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 15: 4680-4685.
24. Boyd DB (2003) Insulin and cancer. Integr Cancer Ther 2: 315-329.
25. Pechlivanis S, Pardini B, Bermejo JL, Wagner K, Naccarati A, et al. (2007) Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer 14: 733-740. (Pubitemid 350074062)
26. Ho GY, Melman A, Liu SM, Li M, Yu H, et al. (2003) Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer 88: 263-269. (Pubitemid 36255846)
27. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, et al. (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871.
28. Edge SB, Byrd D.R, Compton C.C, Fritz A.G, Greene F.L, Trotti A, Eds (2009) AJCC Cancer Staging Manual, 7th edition. Springer: New York, USA: 143-159.
29. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials 17: 343-346. (Pubitemid 26342716)
30. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008) Interaction of EGFR 497Arg.Lys with EGF +61A.G polymorphism: Modulation of risk in Esophageal cancer. Oncology Research 17: 167-174.
31. Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, et al. (2007) Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic Polymorphisms on survival outcome - An exploratory study in squamous cell esophageal cancer. Cancer Biology & Therapy 6: 1553-1558. (Pubitemid 351590326)
32. Bradbury PA, Zhai RH, Ma C, Xu W, Hopkins J, et al. (2009) Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis. Clinical Cancer Research 15: 4680-4685.
33. Hildebrandt MAT, Yang HS, Hung MC, Izzo JG, Huang M, et al. (2009) Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. Journal of Clinical Oncology 27: 857-871.
34. Winder T, Zhang W, Yang DY, Ning Y, Bohanes P, et al. (2010) Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients. Clinical Cancer Research 16: 5591-5602.
35. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, et al. (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359: 397-401. (Pubitemid 34158948)
36. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, et al. (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34: 383-394. (Pubitemid 36935331)
37. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, et al. (2008) A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 14: 3216-3222.
38. Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, et al. (2007) Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther 6: 1553-1558. (Pubitemid 351590326)
39. Bell GI, Fong NM, Stempien MM, Wormsted MA, Caput D, et al. (1986) Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res 14: 8427-8446.
40. Carpenter G (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881-914.
41. Hosgood HD, 3rd, Menashe I, Shen M, Yeager M, Yuenger J, et al. (2008) Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 29: 1938-1943.
42. Parries G, Chen K, Misono KS, Cohen S (1995) The human urinary epidermal growth factor (EGF) precursor. Isolation of a biologically active 160-kilodalton heparin-binding pro-EGF with a truncated carboxyl terminus. J Biol Chem 270: 27954-27960.
43. Mroczkowski B, Reich M, Whittaker J, Bell GI, Cohen S (1988) Expression of human epidermal growth factor precursor cDNA in transfected mouse NIH 3T3 cells. Proc Natl Acad Sci U S A 85: 126-130.
44. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12: 1232-1235. (Pubitemid 30611801)
45. Wang LE, Ma HX, Hale KS, Yin M, Meyer LA, et al. (2012) Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. Journal of Cancer Research and Clinical Oncology 138: 377-385.
46. Moriai T, Kobrin MS, Hope C, Speck L, Korc M (1994) A Variant Epidermal Growth-Factor Receptor Exhibits Altered Type-Alpha Transforming Growth-Factor Binding and Transmembrane Signaling. Proceedings of the National Academy of Sciences of the United States of America 91: 10217-10221. (Pubitemid 24311980)
47. Wang WS, Chen PM, Chiou TJ, Liu JH, Lin JK, et al. (2007) Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clinical Cancer Research 13: 3597-3604.
48. Zhang J, Zhan Z, Wu J, Zhang C, Yang Y, et al. (2013) Association among Polymorphisms in EGFR Gene Exons, Lifestyle and Risk of Gastric Cancer with Gender Differences in Chinese Han Subjects. PLoS One 8: e59254.
49. Inada S, Koto T, Futami K, Arima S, Iwashita A (1999) Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 29: 493-503. (Pubitemid 29313958)
50. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, et al. (1994) Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795-804. (Pubitemid 24237457)
51. Hirai T, Kuwahara M, Yoshida K, Kagawa Y, Hihara J, et al. (1998) Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis Esophagus 11: 221-225. (Pubitemid 29087922)
52. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4: S9-15.